Atlas Trials

MedSIR

56 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch MedSIR

RecordFirmDate
A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations. (NCT07619066)MedSIR2026-10-04
Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer (NCT07367178)MedSIR2026-07-01
A PHASE IB/II STUDY TO EVALUATE SAFETY AND EFFICACY OF BEXMARILIMAB IN COMBINATION WITH DOXORUBICIN IN METASTATIC SOFT-TISSUE SARCOMA (NCT07460986)MedSIR2026-07-01
A COMPREHENSIVE BIOMARKER EVALUATION IN BILIARY TRACT CANCER (NCT07515950)MedSIR2026-07-01
Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (NCT07494448)MedSIR2026-07-01
Platform Trial Assessing Uptake, Safety and Efficacy of Theranostic Agents in Solid Tumors With Active Brain Metastases (NCT07178938)MedSIR2026-04-30
Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC (NCT07134556)MedSIR2026-04-01
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer (NCT07195227)MedSIR2026-03-24
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype (NCT06486883)MedSIR2025-06-30
REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis (NCT06315010)MedSIR2025-06-27
Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases (NCT06676917)MedSIR2025-06-01
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer (NCT06604858)MedSIR2025-05-29
Clinical Study to Evaluate Debio0123 + Sacituzumab Govitecan Combination in TNBC or HR+/HER2- Advanced Breast Cancer (NCT06612203)MedSIR2025-01-17
Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic Progression (NCT06180356)MedSIR2024-12-03
T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (NCT06048718)MedSIR2024-06-05
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population (NCT05708235)MedSIR2024-04-01
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (NCT05865990)MedSIR2023-11-24
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (NCT05659563)MedSIR2023-07-20
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin (NCT05810870)MedSIR2023-05-24
Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED (NCT05520723)MedSIR2023-02-06
Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) (NCT06525675)MedSIR2022-07-18
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer (NCT05227131)MedSIR2022-05-15
POL6326 (Balixafortide) Plus Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer (NCT04826016)MedSIR2022-03-16
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status (NCT05217381)MedSIR2022-02-22
Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents (NCT04710628)MedSIR2021-09-21
Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer (NCT04733118)MedSIR2021-08-05
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL (NCT04603183)MedSIR2021-06-02
CB-103 Plus NSAI In Luminal Advanced Breast Cancer (NCT04714619)MedSIR2021-05-06
Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (NCT04300790)MedSIR2020-10-23
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer (NCT04464174)MedSIR2020-10-08
First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBC (NCT04408118)MedSIR2020-10-05
Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) (NCT04332744)MedSIR2020-09-02
Niraparib Plus Aromatase Inhibitors for Luminal-like(HER2-,ER+) and gBRCA or HDR+ Metastatic Breast Cancer (LUZERN) (NCT04240106)MedSIR2020-06-15
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (NCT04420598)MedSIR2020-05-25
Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma (ORPHEUS) (NCT04231981)MedSIR2020-04-28
Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (NCT03819010)MedSIR2019-05-07
Trial With Eribulin or Eribulin+ Endocrine Therapy in Locally-recurrent or Metastatic Breast Cancer Patients (NCT03795012)MedSIR2019-04-30
Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer (NCT03931551)MedSIR2019-04-30
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (NCT03809988)MedSIR2019-04-05
Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (NCT03222856)MedSIR2017-12-14

Track MedSIR automatically

Every clearance here is in the API, with alerts when new ones post.